OBJECTIVE: To analyze the reliability of an electronic prescription software at primary care (Medoracyl®) to conceal the medication at hospital admission. METHOD: Prospective, comparative study of the home-based validated treatment of patients admitted to the hospital as compared to the one prescribed through Medoracyl®. The medi cation at admission was gathered by medical interview, medi cal records, and revision of the medication brought by the patients; the medication active in Medoracyl® by consulting the application the admission day. The discrepancies between both therapies were analyzed. RESULTS: 47 patients were included with 273 lines of home validated treatments and 274 lines of Medoracyl® treatment. 48 out of 273 lines were in discrepancy (17.6% [95% CI: 13.1- 21.6]). 27 out of 48 were justified, whereas 7.8% represented a discrepancy risk [95% CI: 4.6-11.0]. CONCLUSIONS: Medoracyl® is a useful tool and easy to access that allows knowing more than 90% of the home medication of the patients.
OBJECTIVE: To analyze the reliability of an electronic prescription software at primary care (Medoracyl®) to conceal the medication at hospital admission. METHOD: Prospective, comparative study of the home-based validated treatment of patients admitted to the hospital as compared to the one prescribed through Medoracyl®. The medi cation at admission was gathered by medical interview, medi cal records, and revision of the medication brought by the patients; the medication active in Medoracyl® by consulting the application the admission day. The discrepancies between both therapies were analyzed. RESULTS: 47 patients were included with 273 lines of home validated treatments and 274 lines of Medoracyl® treatment. 48 out of 273 lines were in discrepancy (17.6% [95% CI: 13.1- 21.6]). 27 out of 48 were justified, whereas 7.8% represented a discrepancy risk [95% CI: 4.6-11.0]. CONCLUSIONS:Medoracyl® is a useful tool and easy to access that allows knowing more than 90% of the home medication of the patients.